On Thursday, Extreme Netoperates, Inc (NASDAQ:EXTR)’s shares inclined 2.90% to $3.19.
Extreme Netoperates, Inc. (EXTR) released financial results for the fourth quarter and fiscal year ended June 30, 2015. Fourth quarter GAAP revenue was $149.9 million and non-GAAP revenue was $150.6 million. GAAP net loss for the fourth fiscal quarter was $15.7 million, or $0.16 per share, and non-GAAP net income was $10.1 million, or $0.10 per share. For the full fiscal year 2015, Extreme Netoperates stated GAAP revenue of $552.9 million, contrast to $519.6 million for fiscal 2014. Fiscal year 2015 non-GAAP revenue was $556.0 million contrast to $524.8 million in fiscal 2014. GAAP net loss was $71.6 million, or $0.72 per share, for fiscal 2015, contrast to GAAP net loss of $57.3 million, or $0.60 per share, for fiscal 2014. On a non-GAAP basis, net income for fiscal 2015 was $5.9 million, or $0.06 per diluted share, contrast to $29.5 million, or $0.30 per diluted share for fiscal 2014.
Extreme Netoperates, Inc., together with its auxiliaries, provides wired and wireless network infrastructure equipment, software, and services for enterprises, data centers, and service providers. The company offers Black Diamond products, which deliver modular or chassis-based Ethernet connectivity solutions that have a range of administration and line cards allowing customers to configure and re-purpose the systems; and Summit product family of stackable Ethernet switching systems, which provide a range of connection speeds, various physical presentations, and options to deliver PoE or unpowered standard Ethernet ports.
Sanofi SA (ADR) (NYSE:SNY)’s shares gained 0.69% to $49.57.
Sanofi Pasteur, the vaccines division of Sanofi, declared that Vaccine published positive results from a new analysis of data from a large-scale, multi-center efficacy trial. In this new analysis, researchers observed significantly fewer serious cardio-respiratory events possibly related to influenza (“the flu”) in study participants 65 years of age and older who received a higher-dose split-virus inactivated influenza vaccine (IIV-HD) contrast to a standard-dose split-virus inactivated influenza vaccine (IIV-SD).
In the efficacy trial, a total of 31,989 adults 65 years of age and older were randomly assigned in a 1:1 ratio to receive either IIV-HD (Fluzone® High-Dose vaccine, Sanofi Pasteur, Swiftwater, PA) or IIV-SD (Fluzone vaccine, Sanofi Pasteur) and followed for six to eight months post-vaccination for the occurrence of influenza and serious events, counting events leading to death or hospitalization (or its prolongation), or events considered life-threatening or medically important, or resulting in disability. For the supplementary analysis stated in Vaccine, cardio-respiratory events were grouped into seven categories: pneumonia, asthma, chronic obstructive pulmonary disease (COPD) or bronchial events, influenza (laboratory-confirmed influenza diagnosed outside of normal study procedures), other respiratory events, coronary artery events, congestive heart failure, and cerebrovascular events.
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
At the end of Thursday’s trade, Qlik Technologies Inc (NASDAQ:QLIK)‘s shares surged 1.55% to $38.56.
Qlik® (QLIK), a leader in visual analytics, and Supply Chain Digest (SCDigest), the industry’s premier supply chain administration and logistics publication, recently declared the findings of a global study, Leveraging Supply Chain Data for Competitive Advantage. According to the study, the majority of recently’s supply chain analytics are “looking in the rearview mirror” when it comes to evaluating performance, but realize the potential value of adopting advanced analytics.
More than 40 percent of respondents said they are still almost exclusively backward looking when it comes to data analysis. However the vast majority expressed the belief that predictive analytics would bring value to users enabling them to leverage data at the point of decision. Additionally, more than 88 percent of respondents ranked advanced analytic capabilities as an outstanding or good opportunity for their organization. Respondents also noted that making improvements in data and analytic capabilities was either a high precedingity or something they were already focused on doing.
Qlik Technologies Inc. provides user-driven business intelligence solutions that enable customers to make business decisions. The company develops, commercializes, and implements software products and related services. It offers QlikView, which enables business users to explore data; ask and answer their own stream of questions; and follow their own path to insight on their own, or collaborate across teams and organizations.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), ended its Thursday’s trading session with -6.08% loss, and closed at $18.39.
Momenta Pharmaceuticals, Inc. (MNTA) stated its financial results for the second quarter ended June 30, 2015.
For the second quarter of 2015, the Company stated total revenues of $44.9 million, compriseing primarily of product and milestone revenues regardingthe approval and launch of GlatopaTM (glatiramer acetate injection). Momenta stated a net loss of $(2.2) million, or $(0.04) per share for the second quarter contrast to a net loss of $(26.2) million, or $(0.51) per share for the same period in 2014. At June 30, 2015, the Company had cash, cash equivalents, and marketable securities of $377.2 million.
Second Quarter Highlights and Recent Events
Complex Generics:
GlatopaTM, generic version of daily COPAXONE® 20 mg (glatiramer acetate injection)
- On April 16, 2015, Glatopa was approved by the FDA as the first and only “AP-rated,” substitutable generic version of daily COPAXONE 20 mg.
- On June 18, 2015, the U.S. Court of Appeals for the Federal Circuit (CAFC) again found the remaining patent on daily COPAXONE 20 mg at issue in Teva’s infringement suit to be invalid.
- Sandoz launched Glatopa on June 18, 2015. In the second quarter of 2015, Momenta recorded $19.2 million in product revenues from Glatopa sales, net of a deduction of $9.0 million for reimbursement to Sandoz of the Company’s share of pre-launch Glatopa-related legal expenses.
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. The company’s complex generics programs comprise Enoxaparin sodium injection, a generic version of Lovenox that is used for the prevention and treatment of deep vein thrombosis, and to support the treatment of acute coronary syndromes; and M356, a generic version of Copaxone, which is a complex drug comprising of a synthetic mixture of polypeptide chains for the treatment of patients with relapsing-remitting multiple sclerosis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
